Combination therapies: inhibitors of GABA transaminase and NKCC1
- 专利权人:
- Frances E. Jensen
- 发明人:
- Frances E. Jensen
- 申请号:
- US13069311
- 公开号:
- US08822539B2
- 申请日:
- 2011.03.22
- 申请国别(地区):
- US
- 年份:
- 2014
- 代理人:
- 摘要:
- Inhibitors of NKCC1, such as bumetanide, when coadministered with inhibitors of GABA transaminase, such as vigabatrin, attenuate both the retinal toxicity and the intramyelinic edema.
- 来源网站:
- 中国工程科技知识中心
相关发明人
相关专利
- Inhibit the application of S100A16 what treatment retinal degenerative diseases
- NORRIN REGULATION OF CELLULAR PRODUCTION OF JUNCTION PROTEINS AND USE TO TREAT RETINAL VASCULATURE EDEMA
- METHODS OF USING GAP JUNCTIONS AS THERAPEUTIC TARGETS FOR THE TREATMENT OF DEGENERATIVE DISORDERS OF THE RETINA
- METHODS OF USING GAP JUNCTIONS AS THERAPEUTIC TARGETS FOR THE TREATMENT OF DEGENERATIVE DISORDERS OF THE RETINA
- METHODS OF USING GAP JUNCTIONS AS THERAPEUTIC TARGETS FOR THE TREATMENT OF DEGENERATIVE DISORDERS OF THE RETINA